Trigeminal Neuralgia Treated With Pregabalin in Family Medicine Settings: Its Effect on Pain Alleviation and Cost Reduction
Authors:
- Concepción PérezConcepción Pérez
- María T. SaldañaMSMaría T. Saldaña
- Ana NavarroANAna Navarro
- Silvia MartínezSMSilvia Martínez
- Javier RejasJRJavier Rejas
- 1 May 2009
- journal article
- research article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 49 (5) , 582-590
Abstract
The purpose of this study is to analyze the effect of pregabalin (PGB) on pain alleviation, use of health care and non-health care resources, and associated costs in patients with trigeminal neuralgia under usual clinical practice in primary care settings. Sixty-five PGB-naïve patients receiving PGB as monotherapy (n = 36, 55%) or combined with other drugs (n = 29, 45%) fulfill criteria for inclusion in a secondary analysis from a 12-week, multicenter, observational prospective study aimed to ascertain the cost of illness in subjects with neuropathic pain. Pain is evaluated using the Short Form McGill Pain Questionnaire. Use of health care and non-health care resources and lost workdays equivalents (LWDEs) are also recorded. PGB significantly reduces pain scores, use of health care resources (ancillary tests and unscheduled medical visits), and number of LWDEs. Additional cost of PGB treatment (+euro 174 +/- 106) is broadly compensated for by a reduction in both health care costs (-euro 621 +/-1211, P < .001) and indirect costs (-euro 1210 +/- 1141, P < .001). It is concluded that PGB as monotherapy or combined with other drugs is effective in pain management in patients with trigeminal neuralgia and reduces the cost of illness.Keywords
This publication has 18 references indexed in Scilit:
- Validity and reliability of the Spanish version of the DN4 (Douleur Neuropathique 4 questions) questionnaire for differential diagnosis of pain syndromes associated to a neuropathic or somatic componentHealth and Quality of Life Outcomes, 2007
- Efficacy of Pregabalin in the Treatment of Trigeminal NeuralgiaCephalalgia, 2007
- Gabapentin and pregabalin for chronic neuropathic and early postsurgical pain: current evidence and future directionsCurrent Opinion in Anaesthesiology, 2007
- Pregabalin: A novel γ-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disordersClinical Therapeutics, 2007
- Evidence-based approach to the medical management of trigeminal neuralgiaBritish Journal Of Neurosurgery, 2007
- Patient Burden of Trigeminal Neuralgia: Results from a Cross‐Sectional Survey of Health State Impairment and Treatment Patterns in Six European CountriesPain Practice, 2006
- Chronic pain and reduced work effectiveness: The hidden cost to Australian employersEuropean journal of pain, 2006
- Pregabalin in neuropathic pain: A more “pharmaceutically elegant” gabapentin?The American Journal of Geriatric Pharmacotherapy, 2005
- Clinical characteristics and economic costs of patients with painful neuropathic disordersThe Journal of Pain, 2004
- The short-form McGill pain questionnairePain, 1987